Drug Treatment of Hypertension: Focus on Vascular Health
- 26 September 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 76 (16), 1529-1550
- https://doi.org/10.1007/s40265-016-0642-8
Abstract
Hypertension, the most common preventable risk factor for cardiovascular disease and death, is a growing health burden. Serious cardiovascular complications result from target organ damage including cerebrovascular disease, heart failure, ischaemic heart disease and renal failure. While many systems contribute to blood pressure (BP) elevation, the vascular system is particularly important because vascular dysfunction is a cause and consequence of hypertension. Hypertension is characterised by a vascular phenotype of endothelial dysfunction, arterial remodelling, vascular inflammation and increased stiffness. Antihypertensive drugs that influence vascular changes associated with high BP have greater efficacy for reducing cardiovascular risk than drugs that reduce BP, but have little or no effect on the adverse vascular phenotype. Angiotensin converting enzyme ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve endothelial function and prevent vascular remodelling. Calcium channel blockers also improve endothelial function, although to a lesser extent than ACEIs and ARBs. Mineralocorticoid receptor blockers improve endothelial function and reduce arterial stiffness, and have recently become more established as antihypertensive drugs. Lifestyle factors are essential in preventing the adverse vascular changes associated with high BP and reducing associated cardiovascular risk. Clinicians and scientists should incorporate these factors into treatment decisions for patients with high BP, as well as in the development of new antihypertensive drugs that promote vascular health.Keywords
Funding Information
- British Heart Foundation (CH/12/4/29762, RE/13/5/30177)
This publication has 157 references indexed in Scilit:
- Regular aerobic exercise protects against impaired fasting plasma glucose-associated vascular endothelial dysfunction with agingClinical Science, 2012
- Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocityJournal of Hypertension, 2012
- Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled studyDiabetologia, 2011
- Vascular Endothelial Function and Hypertension: Insights and DirectionsCurrent Hypertension Reports, 2010
- Secondhand smoke (SHS) exposure is associated with circulating markers of inflammation and endothelial function in adult men and womenAtherosclerosis, 2010
- Modulation of Vascular Endothelial Function by Low-Density Lipoprotein Cholesterol With Aging: Influence of Habitual ExerciseAmerican Journal of Hypertension, 2009
- How mitochondria produce reactive oxygen speciesBiochemical Journal, 2008
- Redox Signaling, Vascular Function, and HypertensionAntioxidants and Redox Signaling, 2008
- Angiotensin II induces human TGF-β1 promoter activation: similarity to hyperglycaemiaDiabetologia, 2002
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980